[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Miramar Labs, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":54},{"warningLetters":4,"total":53},[5,30],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":24,"medical_device_id":19,"response_letter_date":19},2695,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-05-04T12:40:00Z\">05\u002F04\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-04T04:00:00Z\">05\u002F04\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fm-six-labs-inc-618701-05042022\">M Six Labs, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved New Drugs\u002FMisbranded\u002FCannabidiol (CBD) Products","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Terry Maxwell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>M Six Labs, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>725 N. Progress Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saukville\u003C\u002Fspan>, \u003Cspan>WI\u003C\u002Fspan> \u003Cspan>53080\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@msixlabs.com\"> sales@msixlabs.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>WARNING LETTER\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>May 4, 2022\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>RE: # 618701\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Dear Terry Maxwell:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fm6labs.com in February 2022 and has determined that you take orders there for various human and animal products, which you represent as containing cannabidiol (CBD) or Delta-8 tetrahydrocannabinol (THC). The claims on your website establish that your products, most of which are available in multiple varieties, “Silver Lake Delta 8 Uncut Glass Dab Syringe,” “Silver Lake CBD MCT Oil Tincture,” “Magnolia Botanicals CBD Avocado Oil Tincture,” “Chaz Ortiz CBD 500mg Essential Balm,” “Magnolia Botanicals CBD 500mg Balm Stick,” “Silver Lake CBD Vegan Chew,” “Nobel Hemp CBD Snapping Rocks,” “Nobel Hemp CBD Chews,” “Nobel Hemp Delta 8 Vegan Gummy,” “Silver Lake Delta 8 Atomic Crystals,” “Silver Lake Delta 8 Tincture,” “Silver Lake Delta 8 Infused Sugar,” “Silver Lake Vegan Chews Delta 8,” “Magnolia Botanicals CBD Canna Rocks Popping Candy,” “Magnolia Botanicals Vegan Hemp Chews,” and “Silver Lake CBD Infused Sugar” (hereinafter referred to as “your CBD and Delta-8 THC products for humans”) are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1). &nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>In addition, your products, which are available in multiple varieties, “Magnolia Botanicals MB Pets Hemp Oil,” “Nobel Hemp Pet Comfort Tincture,” and “Silver Lake Pet Comfort Tincture” (hereinafter referred to as “your CBD-containing products for animals”) are unapproved new animal drugs that are unsafe under section 512(a) of the FD&amp;C Act, 21 U.S.C. 360b(a), and are adulterated under section 501(a)(5) of the FD&amp;C Act, 21 U.S.C. 351(a)(5).&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>FDA has also determined that \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>your “Nobel Hemp CBD Snapping Rocks,” “Nobel Hemp CBD Chews,” “Silver Lake Delta-8 Atomic Crystals,” “Silver Lake Delta 8 Infused Sugar,” “Magnolia Botanicals CBD Canna Rocks Popping Candy,” “Silver Lake CBD Infused Sugar,” and “Magnolia Botanicals Vegan Hemp Chews” food products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act,\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan> 21 U.S.C. 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. Furthermore, it is a prohibited act to introduce your \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>“Nobel Hemp CBD Snapping Rocks,” “Nobel Hemp CBD Chews,” “Magnolia Botanicals CBD Canna Rocks Popping Candy,” “Silver Lake CBD Infused Sugar,” and “Magnolia Botanicals Vegan Hemp Chews”\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>\u003Cspan>\u003Cspan>products into interstate commerce under section 301(ll) of the FD&amp;C Act, 21 U.S.C. 331(ll).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act. You can find specific information about how FDA regulates cannabis-derived products at \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd\">\u003Cspan>\u003Cspan>https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Over the past several years, FDA has warned the public on various illegally marketed CBD-containing products. FDA has also observed a proliferation of products containing another cannabinoid, Delta-8 THC, and has recently expressed serious concerns about products containing Delta-8 THC that include: 1) Delta-8 THC products have not been evaluated or approved by FDA for safe use and may be marketed in ways that put the public health at risk; 2) FDA has received adverse event reports involving Delta-8 THC containing products; 3) Delta-8 THC has psychoactive and intoxicating effects; 4) FDA is concerned about the processes used to create the concentrations of Delta-8 THC claimed in the marketplace; and 5) FDA is concerned about Delta-8 THC products that may be consumed by children, as some packaging and labeling may appeal to children. See \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002F5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc\">\u003Cspan>\u003Cspan>https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002F5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>.&nbsp; This letter is to inform you that your firm markets Delta-8 THC-containing products, and Delta-8 THC may pose a serious health risk to consumers.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>Dietary Supplement Labeling\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Information on your website at https:\u002F\u002Fm6labs.com indicates that you intend to market your CBD products “Silver Lake CBD MCT Oil Tincture” and “Silver Lake CBD Vegan Chew” as dietary supplements. The product webpages display an image appearing to be a supplement facts panel. However, your products cannot be dietary supplements because they do not meet the definition of a dietary supplement under section 201(ff) of the FD&amp;C Act, 21 U.S.C. 321(ff). FDA has concluded, based on available evidence, that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&amp;C Act, 21 U.S.C. 321(ff)(3)(B)(i) and (ii). Under those provisions, if an article (such as CBD) is an active ingredient in a drug product that has been approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355, or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement.\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[1]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa> There is an exception if the substance was “marketed as” a dietary supplement or as a conventional food before the new drug investigations were authorized; however, based on available evidence, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&amp;C Act, but you may present FDA with any evidence that has bearing on this issue.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>Unapproved New Human Drugs\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Based on a review of your website, \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>your CBD and Delta-8 THC products for humans\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan> are\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan> drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Examples of claims from your website https:\u002F\u002Fm6labs.com that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your blog post titled, “What is Hemp Derived Delta 8 THC?” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Fighting Cancer . . . Δ8 may also have cancer-fighting properties . . . [t]he researchers treated mice with cancer for 20 consecutive days with a combination of the isomer and cannabinol. The result? Tumors reduced in size.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Reducing Anxiety . . . Δ8 also has anxiolytic properties . . ..”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Potential Treatment for Weight Disorders”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Δ8 isomer . . . raised levels of acetylcholine, a neurotransmitter, in certain areas of mice brains . . . The relevance of these findings to future dementia research is easy to apprehend when you consider that Alzheimer’s disease is characterized by declining levels of acetylcholine in the human brain.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Δ8 improves cognitive function. In the course of the study, they gave oral doses of the isomer to rats with encephalomyelitis, a damaging inflammation of the brain and the spinal cord, and noticed that the neurological function improved.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“[T]opical Δ8 isomer applications lowered corneal pain and inflammation in rats.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“The isomer offers many benefits . . . include improved appetite, anxiety reduction, pain relief and improved cognitive function. In addition, the isomer has antiemetic and cancer-fighting properties.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your blog post titled, “How Does CBD Make You Feel?” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“CBD helps relieve pain, inflammation, nausea, and seizures in many cases.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“CBD is believed to be helpful in the treatment of insomnia and anxiety.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“People who undergo chemotherapy for cancer often suffer from terrible nausea. In some cases, CBD products may help suppress such nausea.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your blog post titled, “What is CBD and What Does CBD Stand For?” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“From pain to inflammation, depression, and insomnia, cannabidiol has been tried on people to treat a wide variety of health issues. The strongest scientific evidence of its medical effects, however, lies in its ability to treat serious childhood epilepsy in conditions such as the Dravet syndrome.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“[C]annabidiol is of some use in the treatment of some cancers.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“CBD is not a cure-all, but there is anecdotal evidence to show that it can be safe and effective for a variety of health conditions, including autoimmune diseases, metabolic syndrome, digestive disorders, cardiovascular dysfunction, chronic pain, and skin conditions.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your Magnolia Botanicals CBD Avocado Oil Tinctures product webpage \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Avocado oil is rich in antioxidants such as lutein which may help decrease inflammation and blood pressure levels.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your CBD and Delta-8 THC products for human use are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. There are no FDA-approved applications in effect for any of the above-mentioned products. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>Misbranded Human Drugs\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your CBD and Delta-8 THC products for humans are misbranded within the meaning of section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. (See 21 CFR 201.5.) \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>Your CBD and Delta-8 THC products for humans are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners. Therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. Under 21 CFR 201.100(c)(2) and 201.115, FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use because no FDA-approved applications are in effect for these products. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The introduction or delivery for introduction into interstate commerce of misbranded drugs is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>301(ll) and Adulterated Human Foods\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>According to your product labeling, your “Nobel Hemp CBD Snapping Rocks,” “Nobel Hemp CBD Chews,” “Magnolia Botanicals CBD Canna Rocks Popping Candy,” Silver Lake CBD Infused Sugar,” and “Magnolia Botanicals Vegan Hemp Chews” products are foods to which CBD has been added\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>. We note that these products are marketed as containing varying quantities of CBD.&nbsp; &nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>However, you should be aware that it is a prohibited act under section 301(ll) of the FD&amp;C Act, 21 U.S.C. 331(ll), to introduce or deliver for introduction into interstate commerce any food, including animal food, to which has been added a drug approved under section 505 of the FD&amp;C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on the available evidence discussed above, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that section 301(ll) of the FD&amp;C Act, 21 U.S.C. 331(ll), prohibits the introduction into interstate commerce of any food to which CBD has been added, but you may present FDA with any evidence bearing on this issue. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>According to your product labeling, your “Nobel Hemp CBD Snapping Rocks,” “Nobel Hemp CBD Chews,” “Magnolia Botanicals CBD Canna Rocks Popping Candy,” Silver Lake CBD Infused Sugar,” and “Magnolia Botanicals Vegan Hemp Chews” products are foods to which CBD has been added. Therefore, the introduction or delivery for introduction into interstate commerce of those products is a prohibited act under section 301(ll) of the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You should also be aware that, as defined in section 201(s) of the FD&amp;C Act, 21 U.S.C. 321(s), the term “food additive” refers to any substance the intended use of which results in it becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.\u003C\u002Fspan>\u003C\u002Fspan>\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[2]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&amp;C Act, 21 U.S.C. 348(a), and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>There is no food additive regulation that authorizes the use of CBD. We are not aware of any information to indicate that CBD is the subject of a prior sanction (see 21 CFR Part 181). &nbsp;Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>We know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of CBD in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from CBD. Our review of publicly available data associated with the one FDA-approved CBD drug, as well as our review of published scientific literature, identified potential for liver injury from CBD and potentially harmful interactions with certain drugs. In addition, studies in animals have shown that CBD can interfere with the development and function of testes and sperm, decrease testosterone levels, and impair sexual behavior in males. Therefore, based on our review, the use of CBD in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>FDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in a conventional food. Therefore, CBD added to a conventional food is a food additive under section 201(s) of the FD&amp;C Act and is subject to the provisions of section 409 of the FD&amp;C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>Therefore, your “Nobel Hemp CBD Snapping Rocks,” “Nobel Hemp CBD Chews,” “Magnolia Botanicals CBD Canna Rocks Popping Candy,” “Silver Lake CBD Infused Sugar,” and “Magnolia Botanicals Vegan Hemp Chews” products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act because they bear or contain an unsafe food additive. Introduction of these adulterated foods into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Further, according to your product labeling, your “Silver Lake Delta 8 Atomic Crystals” and “Silver Lake Delta 8 Infused Sugar” products are foods to which Delta-8 THC has been added.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>There is no food additive regulation that authorizes the use of Delta-8 THC. We are not aware of any information to indicate that Delta-8 THC is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that Delta-8 THC is GRAS for use in conventional foods.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>We know of no basis for general recognition of safety for Delta-8 THC based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of Delta-8 THC in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from Delta-8 THC. Our review of published scientific literature identified potential for adverse effects on the central nervous and cardiopulmonary systems. In addition, studies in animals have suggested that gestational exposure to Delta-8 THC can interfere with neurodevelopment. Therefore, based on our review, the use of Delta-8 THC in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>FDA is not aware of any other exception to the food additive definition that would apply to Delta-8 THC for use as an ingredient in a conventional food. Therefore, Delta-8 THC added to a conventional food is a food additive under section 201(s) of the FD&amp;C Act and is subject to the provisions of section 409 of the FD&amp;C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. Delta-8 THC is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act. Therefore, your “Silver Lake Delta 8 Atomic Crystals” and “Silver Lake Delta 8 Infused Sugar” products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act because they bear or contain an unsafe food additive. Introduction of these adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>Unapproved New Animal Drugs\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>During our review of your website, https:\u002F\u002Fm6labs.com, FDA determined that your firm is marketing CBD-containing products for animals that are unapproved new animal drugs. Based on our review of your website, your CBD-containing products for animals are drugs under section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals. Further, as discussed below, these products are unapproved new animal drugs and marketing them violates the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Examples of claims observed on your website https:\u002F\u002Fm6labs.com that show the intended use of your products for animals as drugs include, but may not be limited to, the following:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your product page for “Magnolia Botanicals MB Pets Hemp Oil”:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“[S]upport the reduction of symptoms associated with seizure disorders, ease inflammation and pain . . . and reduce anxiety and nervousness.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your product page for “Nobel Hemp Pet Comfort Tincture”:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“[S]upport the reduction of symptoms associated with seizure disorders, ease inflammation and pain . . . and reduce anxiety and nervousness.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your product pages for “Silver Lake Pet Comfort Tincture”:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“[S]upport the reduction of symptoms associated with seizure disorders, may help ease inflammation and pain . . . and could reduce anxiety and nervousness.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>CBD-containing products for animals are “new animal drugs” under section 201(v) of the FD&amp;C Act, 21 U.S.C. 321(v), because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act, 21 U.S.C. 360b, 360ccc, and 360ccc-1. These products are not approved, or index listed by the FDA, and therefore these products are considered unsafe under section 512(a) of the FD&amp;C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&amp;C Act, 21 U.S.C. 351(a)(5). Introduction of these adulterated drugs into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"mailto:FDAADVISORY@fda.hhs.gov\">\u003Cspan>\u003Cspan>FDAADVISORY@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u002FS\u002F\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Donald D. Ashley\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Drug Evaluation and Research\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Food and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Neal Bataller\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Division of Drug Compliance\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Surveillance &amp; Compliance\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Veterinary Medicine\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Food and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Ann M. Oxenham\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Food Safety and Applied Nutrition\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Food and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cdiv>&nbsp;\n\u003Chr>\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[1]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa> \u003Cspan>\u003Cspan>CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex.&nbsp;(See \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect.&nbsp;Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[2]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan> Under section 201(s) of the FD&amp;C Act, 21 U.S.C. 321(s), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&amp;C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nTerry Maxwell\n\nRecipient Title\n\nCEO\n\nM Six Labs, Inc.\n\n725 N. Progress Dr.\n\nSaukville, WI 53080\n\nUnited States\n\nsales@msixlabs.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nMay 4, 2022\n\nRE: # 618701\n\nDear Terry Maxwell:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fm6labs.com in February 2022 and has determined that you take orders there for various human and animal products, which you represent as containing cannabidiol (CBD) or Delta-8 tetrahydrocannabinol (THC). The claims on your website establish that your products, most of which are available in multiple varieties, “Silver Lake Delta 8 Uncut Glass Dab Syringe,” “Silver Lake CBD MCT Oil Tincture,” “Magnolia Botanicals CBD Avocado Oil Tincture,” “Chaz Ortiz CBD 500mg Essential Balm,” “Magnolia Botanicals CBD 500mg Balm Stick,” “Silver Lake CBD Vegan Chew,” “Nobel Hemp CBD Snapping Rocks,” “Nobel Hemp CBD Chews,” “Nobel Hemp Delta 8 Vegan Gummy,” “Silver Lake Delta 8 Atomic Crystals,” “Silver Lake Delta 8 Tincture,” “Silver Lake Delta 8 Infused Sugar,” “Silver Lake Vegan Chews Delta 8,” “Magnolia Botanicals CBD Canna Rocks Popping Candy,” “Magnolia Botanicals Vegan Hemp Chews,” and “Silver Lake CBD Infused Sugar” (hereinafter referred to as “your CBD and Delta-8 THC products for humans”) are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1).\n\nIn addition, your products, which are available in multiple varieties, “Magnolia Botanicals MB Pets Hemp Oil,” “Nobel Hemp Pet Comfort Tincture,” and “Silver Lake Pet Comfort Tincture” (hereinafter referred to as “your CBD-containing products for animals”) are unapproved new animal drugs that are unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and are adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5).\n\nFDA has also determined that your “Nobel Hemp CBD Snapping Rocks,” “Nobel Hemp CBD Chews,” “Silver Lake Delta-8 Atomic Crystals,” “Silver Lake Delta 8 Infused Sugar,” “Magnolia Botanicals CBD Canna Rocks Popping Candy,” “Silver Lake CBD Infused Sugar,” and “Magnolia Botanicals Vegan Hemp Chews” food products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act, 21 U.S.C. 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. Furthermore, it is a prohibited act to introduce your “Nobel Hemp CBD Snapping Rocks,” “Nobel Hemp CBD Chews,” “Magnolia Botanicals CBD Canna Rocks Popping Candy,” “Silver Lake CBD Infused Sugar,” and “Magnolia Botanicals Vegan Hemp Chews” products into interstate commerce under section 301(ll) of the FD&C Act, 21 U.S.C. 331(ll).\n\nAs explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\n\nOver the past several years, FDA has warned the public on various illegally marketed CBD-containing products. FDA has also observed a proliferation of products containing another cannabinoid, Delta-8 THC, and has recently expressed serious concerns about products containing Delta-8 THC that include: 1) Delta-8 THC products have not been evaluated or approved by FDA for safe use and may be marketed in ways that put the public health at risk; 2) FDA has received adverse event reports involving Delta-8 THC containing products; 3) Delta-8 THC has psychoactive and intoxicating effects; 4) FDA is concerned about the processes used to create the concentrations of Delta-8 THC claimed in the marketplace; and 5) FDA is concerned about Delta-8 THC products that may be consumed by children, as some packaging and labeling may appeal to children. See https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002F5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc. This letter is to inform you that your firm markets Delta-8 THC-containing products, and Delta-8 THC may pose a serious health risk to consumers.\n\nDietary Supplement Labeling\n\nInformation on your website at https:\u002F\u002Fm6labs.com indicates that you intend to market your CBD products “Silver Lake CBD MCT Oil Tincture” and “Silver Lake CBD Vegan Chew” as dietary supplements. The product webpages display an image appearing to be a supplement facts panel. However, your products cannot be dietary supplements because they do not meet the definition of a dietary supplement under section 201(ff) of the FD&C Act, 21 U.S.C. 321(ff). FDA has concluded, based on available evidence, that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act, 21 U.S.C. 321(ff)(3)(B)(i) and (ii). Under those provisions, if an article (such as CBD) is an active ingredient in a drug product that has been approved under section 505 of the FD&C Act, 21 U.S.C. 355, or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement.[1] There is an exception if the substance was “marketed as” a dietary supplement or as a conventional food before the new drug investigations were authorized; however, based on available evidence, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act, but you may present FDA with any evidence that has bearing on this issue.\n\nUnapproved New Human Drugs\n\nBased on a review of your website, your CBD and Delta-8 THC products for humans are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims from your website https:\u002F\u002Fm6labs.com that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\n\nOn your blog post titled, “What is Hemp Derived Delta 8 THC?”\n\n“Fighting Cancer . . . Δ8 may also have cancer-fighting properties . . . [t]he researchers treated mice with cancer for 20 consecutive days with a combination of the isomer and cannabinol. The result? Tumors reduced in size.”\n\n“Reducing Anxiety . . . Δ8 also has anxiolytic properties . . ..”\n\n“Potential Treatment for Weight Disorders”\n\n“Δ8 isomer . . . raised levels of acetylcholine, a neurotransmitter, in certain areas of mice brains . . . The relevance of these findings to future dementia research is easy to apprehend when you consider that Alzheimer’s disease is characterized by declining levels of acetylcholine in the human brain.”\n\n“Δ8 improves cognitive function. In the course of the study, they gave oral doses of the isomer to rats with encephalomyelitis, a damaging inflammation of the brain and the spinal cord, and noticed that the neurological function improved.”\n\n“[T]opical Δ8 isomer applications lowered corneal pain and inflammation in rats.”\n\n“The isomer offers many benefits . . . include improved appetite, anxiety reduction, pain relief and improved cognitive function. In addition, the isomer has antiemetic and cancer-fighting properties.”\n\nOn your blog post titled, “How Does CBD Make You Feel?”\n\n“CBD helps relieve pain, inflammation, nausea, and seizures in many cases.”\n\n“CBD is believed to be helpful in the treatment of insomnia and anxiety.”\n\n“People who undergo chemotherapy for cancer often suffer from terrible nausea. In some cases, CBD products may help suppress such nausea.”\n\nOn your blog post titled, “What is CBD and What Does CBD Stand For?”\n\n“From pain to inflammation, depression, and insomnia, cannabidiol has been tried on people to treat a wide variety of health issues. The strongest scientific evidence of its medical effects, however, lies in its ability to treat serious childhood epilepsy in conditions such as the Dravet syndrome.”\n\n“[C]annabidiol is of some use in the treatment of some cancers.”\n\n“CBD is not a cure-all, but there is anecdotal evidence to show that it can be safe and effective for a variety of health conditions, including autoimmune diseases, metabolic syndrome, digestive disorders, cardiovascular dysfunction, chronic pain, and skin conditions.”\n\nOn your Magnolia Botanicals CBD Avocado Oil Tinctures product webpage\n\n“Avocado oil is rich in antioxidants such as lutein which may help decrease inflammation and blood pressure levels.”\n\nYour CBD and Delta-8 THC products for human use are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. There are no FDA-approved applications in effect for any of the above-mentioned products. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nMisbranded Human Drugs\n\nYour CBD and Delta-8 THC products for humans are misbranded within the meaning of section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. (See 21 CFR 201.5.) Your CBD and Delta-8 THC products for humans are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners. Therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. Under 21 CFR 201.100(c)(2) and 201.115, FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use because no FDA-approved applications are in effect for these products.\n\nThe introduction or delivery for introduction into interstate commerce of misbranded drugs is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\n301(ll) and Adulterated Human Foods\n\nAccording to your product labeling, your “Nobel Hemp CBD Snapping Rocks,” “Nobel Hemp CBD Chews,” “Magnolia Botanicals CBD Canna Rocks Popping Candy,” Silver Lake CBD Infused Sugar,” and “Magnolia Botanicals Vegan Hemp Chews” products are foods to which CBD has been added. We note that these products are marketed as containing varying quantities of CBD.\n\nHowever, you should be aware that it is a prohibited act under section 301(ll) of the FD&C Act, 21 U.S.C. 331(ll), to introduce or deliver for introduction into interstate commerce any food, including animal food, to which has been added a drug approved under section 505 of the FD&C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD. There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on the available evidence discussed above, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that section 301(ll) of the FD&C Act, 21 U.S.C. 331(ll), prohibits the introduction into interstate commerce of any food to which CBD has been added, but you may present FDA with any evidence bearing on this issue.\n\nAccording to your product labeling, your “Nobel Hemp CBD Snapping Rocks,” “Nobel Hemp CBD Chews,” “Magnolia Botanicals CBD Canna Rocks Popping Candy,” Silver Lake CBD Infused Sugar,” and “Magnolia Botanicals Vegan Hemp Chews” products are foods to which CBD has been added. Therefore, the introduction or delivery for introduction into interstate commerce of those products is a prohibited act under section 301(ll) of the FD&C Act.\n\nYou should also be aware that, as defined in section 201(s) of the FD&C Act, 21 U.S.C. 321(s), the term “food additive” refers to any substance the intended use of which results in it becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.[2]\n\nFood additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&C Act, 21 U.S.C. 348(a), and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nThere is no food additive regulation that authorizes the use of CBD. We are not aware of any information to indicate that CBD is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\n\nWe know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of CBD in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from CBD. Our review of publicly available data associated with the one FDA-approved CBD drug, as well as our review of published scientific literature, identified potential for liver injury from CBD and potentially harmful interactions with certain drugs. In addition, studies in animals have shown that CBD can interfere with the development and function of testes and sperm, decrease testosterone levels, and impair sexual behavior in males. Therefore, based on our review, the use of CBD in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\n\nFDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in a conventional food. Therefore, CBD added to a conventional food is a food additive under section 201(s) of the FD&C Act and is subject to the provisions of section 409 of the FD&C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act. Therefore, your “Nobel Hemp CBD Snapping Rocks,” “Nobel Hemp CBD Chews,” “Magnolia Botanicals CBD Canna Rocks Popping Candy,” “Silver Lake CBD Infused Sugar,” and “Magnolia Botanicals Vegan Hemp Chews” products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act because they bear or contain an unsafe food additive. Introduction of these adulterated foods into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nFurther, according to your product labeling, your “Silver Lake Delta 8 Atomic Crystals” and “Silver Lake Delta 8 Infused Sugar” products are foods to which Delta-8 THC has been added.\n\nThere is no food additive regulation that authorizes the use of Delta-8 THC. We are not aware of any information to indicate that Delta-8 THC is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that Delta-8 THC is GRAS for use in conventional foods.\n\nWe know of no basis for general recognition of safety for Delta-8 THC based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of Delta-8 THC in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from Delta-8 THC. Our review of published scientific literature identified potential for adverse effects on the central nervous and cardiopulmonary systems. In addition, studies in animals have suggested that gestational exposure to Delta-8 THC can interfere with neurodevelopment. Therefore, based on our review, the use of Delta-8 THC in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\n\nFDA is not aware of any other exception to the food additive definition that would apply to Delta-8 THC for use as an ingredient in a conventional food. Therefore, Delta-8 THC added to a conventional food is a food additive under section 201(s) of the FD&C Act and is subject to the provisions of section 409 of the FD&C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. Delta-8 THC is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act. Therefore, your “Silver Lake Delta 8 Atomic Crystals” and “Silver Lake Delta 8 Infused Sugar” products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act because they bear or contain an unsafe food additive. Introduction of these adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nUnapproved New Animal Drugs\n\nDuring our review of your website, https:\u002F\u002Fm6labs.com, FDA determined that your firm is marketing CBD-containing products for animals that are unapproved new animal drugs. Based on our review of your website, your CBD-containing products for animals are drugs under section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals. Further, as discussed below, these products are unapproved new animal drugs and marketing them violates the FD&C Act.\n\nExamples of claims observed on your website https:\u002F\u002Fm6labs.com that show the intended use of your products for animals as drugs include, but may not be limited to, the following:\n\nOn your product page for “Magnolia Botanicals MB Pets Hemp Oil”:\n\n“[S]upport the reduction of symptoms associated with seizure disorders, ease inflammation and pain . . . and reduce anxiety and nervousness.”\n\nOn your product page for “Nobel Hemp Pet Comfort Tincture”:\n\n“[S]upport the reduction of symptoms associated with seizure disorders, ease inflammation and pain . . . and reduce anxiety and nervousness.”\n\nOn your product pages for “Silver Lake Pet Comfort Tincture”:\n\n“[S]upport the reduction of symptoms associated with seizure disorders, may help ease inflammation and pain . . . and could reduce anxiety and nervousness.”\n\nYour CBD-containing products for animals are “new animal drugs” under section 201(v) of the FD&C Act, 21 U.S.C. 321(v), because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\n\nTo be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act, 21 U.S.C. 360b, 360ccc, and 360ccc-1. These products are not approved, or index listed by the FDA, and therefore these products are considered unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5). Introduction of these adulterated drugs into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\n* * *\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n\u002FS\u002F\n\nNeal Bataller\n\nDirector\n\nDivision of Drug Compliance\n\nOffice of Surveillance & Compliance\n\nCenter for Veterinary Medicine\n\nFood and Drug Administration\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\n[1] CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&C Act.\n\n[2] Under section 201(s) of the FD&C Act, 21 U.S.C. 321(s), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.","M Six Labs, Inc.","m-six-labs-inc-618701-05042022","2026-08-18T06:42:29.262718+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fm-six-labs-inc-618701-05042022","2026-10-26T08:09:17.974171+00:00","Warning Letter","Issued","2022-05-04","618701","Animal & VeterinaryDrugsFood & Beverages","Terry Maxwell","2026-08-20T01:56:37.865+00:00","Via Email",{"id":31,"raw":32,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":48,"body_fetched_at":49,"delivery_method":50,"recipient_title":19,"reference_number":51,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},389,[33,34,35,36,37,13,13,13],"\u003Ctime datetime=\"2025-12-23T05:00:00Z\">12\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-09T05:00:00Z\">12\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsv-labs-corporation-716503-12092025\">SV Labs Corporation\u003C\u002Fa>","Center for Veterinary Medicine","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-26\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Graham Orriss\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>SV Labs Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>480 Airport Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Watsonville\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>95076\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-26\u003C\u002Fp>\u003Cp>December 9, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Orriss:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, SV Labs Prescott Corporation, FEI 2130687, at 1115 Dexter Street North, Prescott, Wisconsin, from June 10 to 13, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your July 7, 2025, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm did not adequately investigate out-of-specification (OOS) results associated with your over-the-counter (OTC) human and animal drug products contract manufactured by your facility.\u003C\u002Fp>\u003Cp>For example, an OTC SPF 30 sunscreen lotion human drug product lot failed your total aerobic microbial count specification with a “too numerous to count” (TNTC) result. Your firm released the lot to your customer without investigating the cause of the microbial failure. During a previous FDA inspection, your firm was also cited for releasing drug product lots with failing microbial results without conducting proper investigations.\u003C\u002Fp>\u003Cp>On September 17, 2025, FDA held a teleconference with you to discuss SPF 30 sunscreen lotion human drug product, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During that call, you agreed to voluntarily recall this lot.\u003C\u002Fp>\u003Cp>Your firm identified \u003Cem>Burkholderia cepacia complex\u003C\u002Fem> \u003Cem>(BCC)\u003C\u002Fem> in an OTC topical fungicide animal drug product lot with production line swab samples confirming growth of gram-negative rods consistent with \u003Cem>BCC\u003C\u002Fem>. While your firm rejected the affected lot and increased cleaning and sanitization of the production line, your investigation was inadequate. You failed to extend the investigation to other potentially impacted batches manufactured on the contaminated equipment and did not adequately evaluate the water system as a potential source of contamination, despite documented water system failures. Since 2023, your firm has recorded numerous water system failures, including uninvestigated microbial tests with TNTC results.\u003C\u002Fp>\u003Cp>In your response, you acknowledge past inconsistent compliance with your OOS investigation procedures, which you state has been corrected. We note your additional commitments to conduct a retrospective review of manufacturing records to identify other lots with OOS results that you released to the market. You also committed to implementing process improvement corrective action and preventive actions (CAPAs), updating standard operating procedures (SOPs), and training personnel.\u003C\u002Fp>\u003Cp>Your response is inadequate because it lacks a thorough market suitability analysis for the released sunscreen lot with failing results. Your analysis should include an assessment of risk to consumers and justification for leaving a potentially contaminated product on the market. Additionally, your 12-month retrospective review timeframe is insufficient and should be expanded to cover all products within expiry dates to identify products still in use by consumers. Your response also fails to adequately assess the significance of \u003Cem>BCC\u003C\u002Fem> contamination across your entire product portfolio, particularly given your water system’s documented history of failing microbial test results.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective, independent review of all manufactured drug products currently in the U.S. market and within expiry as of the date of this letter, and a report summarizing the findings of the analysis. If such review reveals substandard quality drug products (including lots with OOS results), take rapid corrective actions, such as notifying customers and market action.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting BCC testing of retain samples to determine the quality of all batches of drug products distributed to the United States that are within expiry as of the date of this letter, and a summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and market action.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, the following:\u003Cbr>o Quality unit oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>o Adequately scoping of each investigation and its CAPA\u003Cbr>o Revised OOS investigation procedures with these and other remediations\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm has not demonstrated that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water that you use as a component is suitable for aqueous-based drug product manufacturing and, at a minimum, meets the United States Pharmacopeia (USP) \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water monograph and appropriate microbial limits.\u003C\u002Fp>\u003Cp>Your legacy \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system included two dead legs that create stagnant areas, fostering biofilm development and microbial contamination. This risk is compounded by your documented history of water system and drug product microbial failures which include TNTC results. These fundamental design deficiencies posed contamination risks to all products manufactured using this water.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that your facility experienced significant water system deficiencies that required comprehensive remediation efforts and installation of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system capable of producing water suitable for its intended purpose. Your response also includes corrective actions such as decommissioning your legacy system, implementing controlled data collection forms, retraining staff on good documentation practices, updating water monitoring SOPs and conducting an impact analysis of products manufactured prior to the improvements.\u003C\u002Fp>\u003Cp>Your response is inadequate. Although you commit to decommissioning the legacy system after validating your new water system, your response does not provide supportive documentation to demonstrate that the new water system is validated for its intended use. Additionally, your response lacks adequate details to ensure that your sampling, testing, and monitoring procedures can meet USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water monograph requirements.\u003C\u002Fp>\u003Cp>Pharmaceutical water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the water system.\u003Cbr>o Validation report for the water system obtained after an appropriately designed system has been installed. Include the system validation protocol, the complete test results, and the final validation report.\u003C\u002Fli>\u003Cli>Your total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your products.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>A procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm lacks process validation studies to demonstrate reproducibility and control of manufacturing processes to ensure uniform product quality. Your firm's extensive history of assay failures in both animal and human over-the-counter drug products, requiring reprocessing indicates poor manufacturing control. Additionally, your firm’s cleaning procedures for shared equipment, particularly filling equipment used to manufacture multiple products including drug products, have not been validated.\u003C\u002Fp>\u003Cp>In your response, you commit to validating your OTC drug product manufacturing processes and equipment cleaning procedures in established timeframes. You also state that you will conduct a retrospective product review.\u003C\u002Fp>\u003Cp>Your response is inadequate. It lacks sufficient details regarding your planned retrospective review of drug products manufactured using unvalidated processes with no clarification on whether the analysis will encompass lots that failed assay testing or underwent reprocessing. Furthermore, while your firm recognizes the use of multiple potent and chemically diverse substances at the facility, your response fails to identify these substances and does not commit to performing a risk assessment to determine if these compounds are processed on shared equipment.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle along with associated procedures. Describe your program for process performance qualification and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing process performance qualification for each of your marketed drug products. Also provide a risk assessment and any follow up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s) and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>o Drugs with higher toxicities\u003Cbr>o Drugs with higher drug potencies\u003Cbr>o Drugs of lower solubility in their cleaning solvents\u003Cbr>o Drugs with characteristics that make them difficult to clean\u003Cbr>o Swabbing locations for areas that are most difficult to clean\u003Cbr>o Maximum hold times before cleaning.\u003C\u002Fli>\u003Cli>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fli>\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Appropriate controls were exercised over computer systems to ensure only authorized personnel make changes to master production and control records or other records (21 CFR 211.68(b)).\u003C\u002Fli>\u003Cli>Adequate laboratory controls were established with proper specifications, standards, sampling plans, and test procedures to ensure materials and drug products meet required identity, strength, quality, and purity standards (21 CFR 211.160(b)).\u003C\u002Fli>\u003Cli>An adequate written stability testing program for drug products (21 CFR 211.166(a)).\u003C\u002Fli>\u003Cli>Laboratory records included complete data from all required tests for compliance with specifications and standards (21 CFR 211.194(a)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you provide corrective actions for each deficiency with specific timeframes.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to address the systemic quality deficiencies identified during the inspection. The observed lapses, including but not limited to laboratory controls, documentation practices, and data integrity controls, many of which were also identified during previous inspections, indicate fundamental weaknesses in the QU’s oversight function. The proposed corrective actions do not adequately demonstrate how you will strengthen quality oversight to ensure ongoing compliance with CGMP requirements.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fli>\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, you should engage a consultant, qualified as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2130687 and ATTN: Rory Geyer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Jill P. Furman, J.D.\u003Cbr>Director\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research&nbsp;\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Dillard H Woody Jr.\u003Cbr>Acting Drug Compliance Director\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Return Receipt Requested\n\nReference #:\n\n320-26-26\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Graham Orriss\n\nRecipient Title\n\nChief Executive Officer\n\nSV Labs Corporation\n\n480 Airport Boulevard\n\nWatsonville, CA 95076\n\nUnited States\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWarning Letter 320-26-26\nDecember 9, 2025\nDear Mr. Orriss:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, SV Labs Prescott Corporation, FEI 2130687, at 1115 Dexter Street North, Prescott, Wisconsin, from June 10 to 13, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your July 7, 2025, response to our Form FDA 483 in detail.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm did not adequately investigate out-of-specification (OOS) results associated with your over-the-counter (OTC) human and animal drug products contract manufactured by your facility.\nFor example, an OTC SPF 30 sunscreen lotion human drug product lot failed your total aerobic microbial count specification with a “too numerous to count” (TNTC) result. Your firm released the lot to your customer without investigating the cause of the microbial failure. During a previous FDA inspection, your firm was also cited for releasing drug product lots with failing microbial results without conducting proper investigations.\nOn September 17, 2025, FDA held a teleconference with you to discuss SPF 30 sunscreen lotion human drug product, lot (b)(4). During that call, you agreed to voluntarily recall this lot.\nYour firm identified Burkholderia cepacia complex (BCC) in an OTC topical fungicide animal drug product lot with production line swab samples confirming growth of gram-negative rods consistent with BCC. While your firm rejected the affected lot and increased cleaning and sanitization of the production line, your investigation was inadequate. You failed to extend the investigation to other potentially impacted batches manufactured on the contaminated equipment and did not adequately evaluate the water system as a potential source of contamination, despite documented water system failures. Since 2023, your firm has recorded numerous water system failures, including uninvestigated microbial tests with TNTC results.\nIn your response, you acknowledge past inconsistent compliance with your OOS investigation procedures, which you state has been corrected. We note your additional commitments to conduct a retrospective review of manufacturing records to identify other lots with OOS results that you released to the market. You also committed to implementing process improvement corrective action and preventive actions (CAPAs), updating standard operating procedures (SOPs), and training personnel.\nYour response is inadequate because it lacks a thorough market suitability analysis for the released sunscreen lot with failing results. Your analysis should include an assessment of risk to consumers and justification for leaving a potentially contaminated product on the market. Additionally, your 12-month retrospective review timeframe is insufficient and should be expanded to cover all products within expiry dates to identify products still in use by consumers. Your response also fails to adequately assess the significance of BCC contamination across your entire product portfolio, particularly given your water system’s documented history of failing microbial test results.\nIn response to this letter, provide:\nA retrospective, independent review of all manufactured drug products currently in the U.S. market and within expiry as of the date of this letter, and a report summarizing the findings of the analysis. If such review reveals substandard quality drug products (including lots with OOS results), take rapid corrective actions, such as notifying customers and market action.\nAn action plan and timelines for conducting BCC testing of retain samples to determine the quality of all batches of drug products distributed to the United States that are within expiry as of the date of this letter, and a summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and market action.\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, the following:\no Quality unit oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\no Adequately scoping of each investigation and its CAPA\no Revised OOS investigation procedures with these and other remediations\n2. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\nYour firm has not demonstrated that the (b)(4) water that you use as a component is suitable for aqueous-based drug product manufacturing and, at a minimum, meets the United States Pharmacopeia (USP) (b)(4) Water monograph and appropriate microbial limits.\nYour legacy (b)(4) water system included two dead legs that create stagnant areas, fostering biofilm development and microbial contamination. This risk is compounded by your documented history of water system and drug product microbial failures which include TNTC results. These fundamental design deficiencies posed contamination risks to all products manufactured using this water.\nIn your response, you acknowledge that your facility experienced significant water system deficiencies that required comprehensive remediation efforts and installation of a new (b)(4) water system capable of producing water suitable for its intended purpose. Your response also includes corrective actions such as decommissioning your legacy system, implementing controlled data collection forms, retraining staff on good documentation practices, updating water monitoring SOPs and conducting an impact analysis of products manufactured prior to the improvements.\nYour response is inadequate. Although you commit to decommissioning the legacy system after validating your new water system, your response does not provide supportive documentation to demonstrate that the new water system is validated for its intended use. Additionally, your response lacks adequate details to ensure that your sampling, testing, and monitoring procedures can meet USP (b)(4) Water monograph requirements.\nPharmaceutical water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\nIn response to this letter, provide:\nA comprehensive remediation plan for the design, control, and maintenance of the water system.\no Validation report for the water system obtained after an appropriately designed system has been installed. Include the system validation protocol, the complete test results, and the final validation report.\nYour total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your products.\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\nA procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) water system. Ensure that the total count limits for your (b)(4) water are appropriately stringent in view of the intended use of each of the products produced by your firm.\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets (b)(4) Water USP monograph specifications and appropriate microbial limits.\n3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm lacks process validation studies to demonstrate reproducibility and control of manufacturing processes to ensure uniform product quality. Your firm's extensive history of assay failures in both animal and human over-the-counter drug products, requiring reprocessing indicates poor manufacturing control. Additionally, your firm’s cleaning procedures for shared equipment, particularly filling equipment used to manufacture multiple products including drug products, have not been validated.\nIn your response, you commit to validating your OTC drug product manufacturing processes and equipment cleaning procedures in established timeframes. You also state that you will conduct a retrospective product review.\nYour response is inadequate. It lacks sufficient details regarding your planned retrospective review of drug products manufactured using unvalidated processes with no clarification on whether the analysis will encompass lots that failed assay testing or underwent reprocessing. Furthermore, while your firm recognizes the use of multiple potent and chemically diverse substances at the facility, your response fails to identify these substances and does not commit to performing a risk assessment to determine if these compounds are processed on shared equipment.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle along with associated procedures. Describe your program for process performance qualification and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing process performance qualification for each of your marketed drug products. Also provide a risk assessment and any follow up actions to be taken for the distributed drug products produced without performing any process validation studies.\nProcess performance protocol(s) and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\nAppropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher drug potencies\no Drugs of lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning.\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\nAppropriate controls were exercised over computer systems to ensure only authorized personnel make changes to master production and control records or other records (21 CFR 211.68(b)).\nAdequate laboratory controls were established with proper specifications, standards, sampling plans, and test procedures to ensure materials and drug products meet required identity, strength, quality, and purity standards (21 CFR 211.160(b)).\nAn adequate written stability testing program for drug products (21 CFR 211.166(a)).\nLaboratory records included complete data from all required tests for compliance with specifications and standards (21 CFR 211.194(a)).\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn your response, you provide corrective actions for each deficiency with specific timeframes.\nYour response is inadequate because it fails to address the systemic quality deficiencies identified during the inspection. The observed lapses, including but not limited to laboratory controls, documentation practices, and data integrity controls, many of which were also identified during previous inspections, indicate fundamental weaknesses in the QU’s oversight function. The proposed corrective actions do not adequately demonstrate how you will strengthen quality oversight to ensure ongoing compliance with CGMP requirements.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, you should engage a consultant, qualified as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2130687 and ATTN: Rory Geyer.\nSincerely,\n\u002FS\u002F\nJill P. Furman, J.D.\nDirector\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nDillard H Woody Jr.\nActing Drug Compliance Director\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine","SV Labs Corporation","sv-labs-corporation-716503-12092025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsv-labs-corporation-716503-12092025","2026-10-26T08:10:08.439344+00:00","2025-12-23","716503","Animal & VeterinaryDrugs Over-the-Counter Drugs","Mr. Graham Orriss","2026-08-19T07:20:29.104+00:00","Via Electronic Mail - Return Receipt Requested","320-26-26","2025-12-09",2,{"510k":55,"classification":56,"enforcement":57,"event":58,"event_backfill":59,"pma":60,"warning_letter":61},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]